Statistics from Altmetric.com
Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007;68:604–10.
Systematic review with meta-analysis.
PsycINFO, MEDLINE (1967–2005), Current Contents (1993–2005), hand searching of reference lists, and contact with pharmaceutical companies.
Study selection and analysis:
The review included randomised, placebo-controlled, double-blind trials comparing the addition of SSRIs to antipsychotics versus adding placebo in people with schizophrenia-spectrum disorder. Main exclusions: comorbid obsessive-compulsive disorder; studies of monoamine oxidase inhibitors, tricyclic, dual action, or atypical antidepressants (for example, bupropion); incomplete or unavailable data; crossover RCTs. Data were extracted by two reviewers, with disagreement resolved by consensus. Hedges’ g effect sizes (which adjust for sample size) were calculated using a random effects model. Heterogeneity was assessed using the Q statistic, with the threshold for significance set at p<0.1. In addition, …
Sources of funding: None reported.
Competing interests: None declared.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.